Stock Analysis

Demant Full Year 2024 Earnings: EPS Misses Expectations

CPSE:DEMANT
Source: Shutterstock

Demant (CPH:DEMANT) Full Year 2024 Results

Key Financial Results

  • Revenue: kr.22.4b (up 3.8% from FY 2023).
  • Net income: kr.2.89b (up 2.5% from FY 2023).
  • Profit margin: 13% (in line with FY 2023).
  • EPS: kr.13.31 (up from kr.12.64 in FY 2023).
earnings-and-revenue-growth
CPSE:DEMANT Earnings and Revenue Growth February 7th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Demant EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.5%.

Looking ahead, revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Denmark.

The company's shares are down 10% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Demant has 1 warning sign we think you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About CPSE:DEMANT

Demant

Operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally.

Undervalued with mediocre balance sheet.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|42.74% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|62.277% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.10|69.118% undervalued
StockMan
StockMan
Community Contributor